Pharmacoepidemiology and Drug Safety 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.---
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 322-331, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 26, 2018 Category: Drugs & Pharmacology Source Type: research
Risk of rhabdomyolysis from 5 ‐α reductase inhibitors
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 351-355, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 25, 2018 Category: Drugs & Pharmacology Source Type: research
---
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 351-355, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 25, 2018 Category: Drugs & Pharmacology Source Type: research
Trends and uptake of new formulations of controlled ‐release oxycodone in Canada
Pharmacoepidemiology and Drug Safety, EarlyView. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 23, 2018 Category: Drugs & Pharmacology Source Type: research
---
Pharmacoepidemiology and Drug Safety, Ahead of Print. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 23, 2018 Category: Drugs & Pharmacology Source Type: research
Drug adherence in treatment resistant and in controlled hypertension —Results from the Swedish Primary Care Cardiovascular Database (SPCCD)
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 315-321, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 19, 2018 Category: Drugs & Pharmacology Source Type: research
A systematic assessment of key design and performance characteristics of drug exposure registries requested by the U.S. Food and Drug Administration
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 299-306, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 19, 2018 Category: Drugs & Pharmacology Source Type: research
---
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 315-321, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 19, 2018 Category: Drugs & Pharmacology Source Type: research
---
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 299-306, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 19, 2018 Category: Drugs & Pharmacology Source Type: research
A systematic assessment of key design and performance characteristics of drug exposure registries requested by the U.S. Food and Drug Administration
ConclusionsThis study suggests clear objectives, patient accrual/retention efforts, adequate analysis plans, and interim reports contribute to the performance of drug exposure registries. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 19, 2018 Category: Drugs & Pharmacology Authors: Yanling Zhao, Ellen Pinnow, Jacqueline M. Major Tags: ORIGINAL REPORT Source Type: research
Bias from restricting to live births when estimating effects of prescription drug use on pregnancy complications: A simulation
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 307-314, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 17, 2018 Category: Drugs & Pharmacology Source Type: research
Beta testing the potential link between the alpha antagonist tamsulosin and dementia
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 349-350, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 17, 2018 Category: Drugs & Pharmacology Source Type: research
---
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 307-314, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 17, 2018 Category: Drugs & Pharmacology Source Type: research
---
Pharmacoepidemiology and Drug Safety,Volume 27, Issue 3, Page 349-350, March 2018. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 17, 2018 Category: Drugs & Pharmacology Source Type: research
Bias from restricting to live births when estimating effects of prescription drug use on pregnancy complications: A simulation
ConclusionsConditioning on live birth can be problematic when studying pregnancy complications. Simple quantitative selection bias analysis in populations restricted to live births may not fully account for selection bias. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 17, 2018 Category: Drugs & Pharmacology Authors: Elizabeth A. Suarez, Suzanne N. Landi, Mitchell C. Conover, Michele Jonsson Funk Tags: ORIGINAL REPORT Source Type: research
